Welcome to our dedicated page for TC BioPharm (Holdings) plc American Depositary Shares news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc American Depositary Shares stock.
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immunotherapy products. The company leverages its proprietary allogeneic gamma-delta T (GD-T) cell platform to create novel therapies aimed at treating cancer and viral infections.
Gamma-delta T cells are unique immune cells that possess characteristics of both the innate and adaptive immune systems, enabling them to distinguish between healthy and diseased tissues. TC BioPharm's approach uses these cells to develop effective treatments for various cancers, including both liquid and solid tumors.
Notable achievements include the initiation of phase 2b/3 pivotal trials for OmnImmune® in the treatment of acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology, which allows for the distribution of frozen cell products to clinics worldwide. The company also maintains a robust pipeline targeting solid tumors and has built a significant intellectual property portfolio.
Recent developments highlight TC BioPharm's dynamic progress:
- March 1, 2024: CEO Bryan Kobel featured on 'The Big Biz Show,' discussing the company's ongoing advancements.
- March 18, 2024: An institutional investor exercised warrants resulting in a net cash infusion of $1.17M, strengthening the company’s financial position.
- March 19, 2024: The company adjourned its General Meeting to gather additional information for a shareholder vote.
- April 2, 2024: Announcement of a new streamlined manufacturing process to increase patient treatment capacity and reduce costs by 85%.
- April 4, 2024: Execution of a non-binding letter of intent to acquire assets focused on CAR-NK cell therapies, enhancing their cancer treatment capabilities.
- May 6, 2024: Agreement for the immediate exercise of certain warrants, raising approximately £3.1M for clinical trials and operations.
- May 6, 2024: Announcement of a second letter of intent to acquire a company developing CAR-T therapies for solid tumors and autoimmune diseases.
- May 15, 2024: Launch of a compassionate use program in the UK for TCB-008, providing new treatment options for patients ineligible for clinical trials.
TC BioPharm continues to focus on expanding its therapeutic platform, leveraging strategic partnerships, and advancing its clinical trials, all while upholding its commitment to improving patient outcomes.
TC BioPharm (Holdings) plc announced the exercise of warrants for £3.1 million gross proceeds. The Company entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase 1,750,000 of the Company's American Depositary Shares. The gross proceeds are expected to be approximately £3.1 million. In return for the exercise of the warrants, the Company will issue new unregistered warrants to purchase 3,500,000 shares of common stock. The offering is expected to close on May 8, 2024. The net proceeds will be used to support an upcoming clinical trial on Acute Myeloid Leukemia.
TC BioPharm (NASDAQ: TCBP) announced the execution of a non-binding letter of intent to acquire a biotechnology company focusing on CAR-T therapies for refractory cancers and solid tumors. The acquisition target has proven the therapeutic potential of its lead CAR-T candidate for various solid tumors and is also developing a novel allogeneic CAR-T for autoimmune diseases. The potential acquisition aims to expand TC BioPharm's therapeutic platform and bring synergies in CAR development expertise, providing multiple shots on goal for the treatment of various indications.
FAQ
What is the current stock price of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
What is the market cap of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
What does TC BioPharm (Holdings) PLC specialize in?
What are gamma-delta T cells?
What is OmnImmune®?
How does TC BioPharm's CryoTC technology work?
What recent financial milestones has TC BioPharm achieved?
What new manufacturing initiatives has TC BioPharm announced?
What is TC BioPharm's compassionate use program?
What are the company's latest strategic acquisitions?
Where can I watch the CEO's interview on 'The Big Biz Show'?
What is TC BioPharm's position in the biopharmaceutical industry?
